APPLICATIONS
CRISPR screens are widely used to uncover novel drug targets. However, they are usually coupled to rather simplistic read-outs, such as cell fitness. At Myllia, we combine CRISPR screening with single-cell RNA sequencing, thus combining CRISPR perturbation with high-content phenotyping.
Drug target identification and validation
Drug target identification and validation
Target identification is the first step of a drug discovery campaign and begins with a screen identifying possible ‘druggable’ targets and their role in the respective disease. Myllia’s unique CROP-Seq screening technology in combination with the best available cellular models including cancer cells and primary T cells supports the identification of critical genes and pathways driving certain disease states.
Mode of action (MoA) analysis
Mode of action (MoA) analysis
Understanding how drugs act in the complex environment of a cell remains one of the critical aspects of drug discovery and development. CROP-Seq delivers transcriptional profiles associated with drug action and indicates which genes impact the drug profile, thus providing unique insights into its mechanism of action. It also uncovers genes that modify drug responses, thus paving the way for combination therapy.
Identification of disease-associated gene function
Identification of disease-associated gene function
Genome-wide association studies have identified thousands of genetic variants that are linked to disease. Unfortunately, many of these loci lie in non-coding regions of the genome. Pinpointing the gene(s) whose expression is regulated by these regions would elucidate novel drug targets that are causally linked to disease. Myllia has built a CRISPR interference platform that can map disease-associated variants to genes in an unbiased fashion.
Genetic screening for primary T cell phenotypes
Genetic screening for primary T cell phenotypes
Engineering of T-lymphocytes has become a crucial factor driving the development of novel cellular medicines and cancer immunotherapies. However, apart from tumor-associated antigens (TAA) and Chimeric Antigen Receptor (CAR) or T Cell Receptor (TCR) discovery, many T cell-intrinsic features involved in CAR-T cell potency remain elusive. At Myllia, CRISPR screens are performed in primary human T cells to study T cell activation, differentiation and phenotypic plasticity. Utilizing dropout viability screens or CROP-Seq at single-cell resolution, we aim to partner with pharmaceutical companies striving to develop the next-generation of CAR-T and TCR-T cell products.